

UNITED STATES DEPARTMENT OF COMMERCIPATED Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		· A	TTORNEY DOCKET NO.
09/554,980	07/17/00	KOLESNICK		R	D6049
_		HM22/1106	一	EXAMINER HAMUD, F	
BENJAMIN ADLER			•		
MCGREGOR & ADLER				ART UNIT	PAPER NUMBER
8011 CANDL	E LANE				<u> </u>
HOUSTON TX 77071		•		1647	- 1
				DATE MAILED:	•
					11/06/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/554,980

Applicant(s)

FUKS et al.

Examiner

Fozia Hamud

Art Unit **1647**



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
Period 1	for Reply	
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	
af	ter SIX (6) MONTHS from the mailing date of this communic	FR 1.136 (a). In no event, however, may a reply be timely filed ation. , a reply within the statutory minimum of thirty (30) days will
be	considered timely.	period will apply and will expire SIX (6) MONTHS from the mailing date of this
CC	mmunication.	
- Any		statute, cause the application to become ABANDONED (35 U.S.C. § 133). mailing date of this communication, even if timely filed, may reduce any
Status		
1) 💢	Responsive to communication(s) filed on Aug 23, 2	
2a) 🗌	This action is FINAL . 2b) 🗓 This act	ion is non-final.
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposi	tion of Claims	
4) 💢	Claim(s) <u>1-7 and 10</u>	is/are pending in the application.
4	a) Of the above, claim(s)	is/are withdrawn from consideration.
5) 💢	Claim(s) <u>1-3 and 10</u>	is/are allowed.
6) 💢	Claim(s) <u>4-7</u>	
7) 🗆	Claim(s)	is/are objected to.
8) 🗆	Claims	are subject to restriction and/or election requirement.
Applica	ition Papers	
9) 🗆	The specification is objected to by the Examiner.	
10)	The drawing(s) filed on is/are	objected to by the Examiner.
11)	The proposed drawing correction filed on	is: a) □ approved b) □ disapproved.
12)	The oath or declaration is objected to by the Exam	iner.
Priority	under 35 U.S.C. § 119	
13)💢	Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d).
a) [All b) □ Some* c) □ None of:	
	1. $\begin{tabular}{ll} oldsymbol{\square} \end{array}$ Certified copies of the priority documents have	re been received.
	2. Certified copies of the priority documents have	re been received in Application No
	application from the International Bure	
	ee the attached detailed Office action for a list of the	
14)∐	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
Attachm	ent(s)	
	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
17) 📙 In	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:

Application/Control Number: 09/554,980

101114111001.07/33 1,5

Art Unit: 1647

DETAILED ACTION

1. Applicant's election with traverse of Group I (claims 1-3) in Paper No.6, filed on August 23

2001 is acknowledged. Applicants' traversal that inventions II and III are specific embodiments of

the method of invention I is persuasive, therefore, inventions of Groups I-III will be examined

together.

Claims 8 and 9 have been canceled. Thus claims 1-7 and 10 are pending and under

consideration.

2. Drawings have been approved by the draftsman.

Specification

2a. It is noted that this application appears to claim subject matter disclosed in prior PCT

Application No. PCT/US98/24806 filed on 20 November 1998, now WO 99/26648 issued on 3 June

1999. A reference to the prior application must be inserted as the first sentence of the specification

of this application if Applicant intends to rely on the filing date of the prior application under 35

U.S.C. 120. See 37 CFR 1.78(a).

It is suggested that below the title of the invention be inserted:

Cross Reference to Related Applications

"This Application is a 371 of "WO 99/26648".

Appropriate correction is required.

2b. This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b).

An abstract on a separate sheet is required.

Claim Rejections - 35 U.S.C. § 112

Page 2

Application/Control Number:09/554,980

Page 3

Art Unit: 1647

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 4-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing

to particularly point out and distinctly claim the subject matter which applicant regards as the

invention.

3a. Regarding claim 4, the phrase "characterized" renders the claim indefinite because it is

unclear whether the limitations following the phrase are part of the claimed invention. See MPEP

§ 2173.05(d).

Claims 5-7 are vague and indefinite so long as they depend on claim 4 for the limitation set

forth directly above.

Conclusion

claims 1-3 and 10 are allowable.

Claims 4-7 would be allowable if they are amended to overcome the rejection under 35

U.S.C. 112, second paragraph.

Prior Art

The prior art made of record and not relied upon is considered pertinent to applicant's

disclosure.

Art Unit: 1647

Haimovitz-Friedman et al. Protein Kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation induced apoptosis, cancer Research. Vol.54, pages 2591-2597, 15 May 1994.

Fuks et al. Basic Fibroblast Growth Factor protects endothelial cells against radiation induced programmed cell death in vitro and in vivo. Cancer Research, Vol.54, pages 2582-2590, 15 May 1994.

Rice et al. Protection from endotoxic shock in mice by pharmoclogic inhibition of phostatidic acid, Proceedings of National Academy of Science, USA. Vol.91, pages 3857-3861. April 1994.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fozia Hamud whose telephone number is (703) 308-8891. The examiner can normally be reached on Monday, Wednesday-Thursday from 6:30AM to 4:00PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4227. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Fozia Hamud Patent Examiner Art Unit 1647 29 October 2001

CHRISTINE J. SAOUD PRIMARY EXAMINER

Christine J. Saoug